v3.26.1
Collaboration, License and Other Arrangements - Schedule of Credits Recognized in Condensed Consolidated Statements of Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Cost of sales $ 392.8 $ 363.0
Research and development expenses 961.6 979.7
Acquired in-process research and development expenses 0.5 19.8
CRISPR JDCA    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Cost of sales 23.1 36.2
Research and development expenses 16.1 16.0
Acquired in-process research and development expenses $ 0.0 $ 12.5